TNF alpha antagonist-induced lupus-like syndrome: Report and review of the literature with implications for treatment with alternative TNF alpha antagonists

International Journal of Dermatology

Volumn 50, Issue 5, 2011, Pages 619-625

  Williams, Victoria L ^a   Cohen, Philip R ^b,c,d  

^a Houston   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d University of Texas Health Science Center at Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE SULFATE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; PATHOGENESIS; RHEUMATOID ARTHRITIS; SKIN BIOPSY;

ADRENAL CORTEX HORMONES; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955003756     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.04871.x     Document Type: Article

References (32)

1. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-279.
2. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E. Adverse cutaneous reactions induced by TNF alpha antagonist therapy. S Med J 2009; 102: 1133-1140.
3. Exarchou SA, Voulgari PV, Markatseli TE, et al. Immune-mediated skin lesions in patients treated with anti-tumor necrosis factor alpha inhibitors. Scand J Rheumatol 2009; 38: 328-331.
4. Aikaterini-Evaggelia M, Matekovits A, Dessinioti C, et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009; 61: 486-504.
5. Wetter DA, Davis MDP. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clinic Proc 2009; 84: 979-984.
6. Marzano AV, Vezzoli P, Crosti C. Drug induced lupus: an update on its dermatological aspects. Lupus 2009; 18: 935-940.
7. Costa MF, Said NR, Zimmermann B. Drug induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008; 37: 381-387.
8. Kocharla L, Mongey AB. Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? Lupus 2009; 18: 169-171.
9. Bout-Tabaku S, Rivas-Chacon R, Restrepo R. Systemic lupus erythematosus in a patient with etanercept for polyarticular juvenile rheumatoid arthritis. J Rheumatol 2007; 34: 2503-2504.
10. Abunasser J, Forouhar FA, Metersky ML. Etanercept-induced lupus erythematosus presenting as a unilateral pleural effusion. Chest 2008; 134: 850-853.
11. Rajakulendran S, Deighton C. Adverse dermatological reactions in rheumatoid arthritis patients treated with etanercept, an anti-TNF-alpha drug. Curr Drug Saf 2006; 1: 259-264.
12. Kang M, Lee Y, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci 2006; 21: 946-949.
13. Statkute L, Ruderman EM. Novel TNF antagonists for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 2010; 19: 105-115.
14. De Bant M, Sibilia J, Le Loet X, et al., with the Club Rhumatismes Inflammation. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French survey. Arth Res Ther 2005; 7: R545-R551.
15. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology 2009; 48: 716-720.
16. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007; 86: 242-251.
17. Manson JJ, Rahman A. Systemic lupus erythematosus. Orphanet J Rare Dis 2006; 1: 6.
18. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007; 1108: 166-182.
19. McCauliffe DP. Cutaneous lupus erythematosus. Sem Cutan Med Surg 2001; 20: 14-26.
20. Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin 2002; 20: 373-385.
21. De Rycke L, Baeten D, Kruithof E, et al. The effect of TNF alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005; 14: 931-937.
22. Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 2005; 1051: 559-569.
23. Kerbleski JF, Gottieb AB. Dermatological complications and safety of anti-TNF treatments. Gut 2009; 58: 1033-1039.
24. D'Auria F, Rovere-Querini P, Giazzon M, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumor necrosis factor-alpha antibodies. J Intern Med 2004; 255: 409-418.
25. Ferraccioli G, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002; 62: 358-361.
26. Via CS, Shustov A, Rus V, et al. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001; 167: 6821-6826.
27. Comby E, Tanaff P, Mariotte D, et al. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis and long-term infliximab therapy. J Rheumatol 2006; 33: 24-30.
28. Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 1998; 18: 59-62.
29. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arth Rheum 2000; 43: 2383-2390.
30. Erikkson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005; 64: 403-407.
31. Ledingham J, Deighton C. British Society for Rheumatology Standards, Guidelines and Audit Working Group (SGAWG): update on the British Society for Rheumatology guidelines for prescribing TNF blockade in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005; 44: 157-163.
32. Cush JJ. Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 2004; 22: S141-S147.